title: Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure.
abstract: The purpose of this study was to prospectively analyze the relationship between the post-transplant anti-HLA class I and/or class II panel reactive antibodies and graft failure due to chronic allograft nephropathy (CAN). We studied 512 first kidney recipients transplanted at a single center, with a graft functioning for at least 3 years. A single blood sample was collected from each patient for antibody evaluation. The median posttransplant time after blood collection was 4.4 years and did not differ between patients with (n = 91) or without anti-HLA antibodies (n = 421). Female gender, pregnancies and blood transfusions were associated with the presence of anti-HLA class I antibodies. Graft function deterioration was associated with anti-HLA class II antibodies. Multivariate analysis showed independent association for creatinine levels (RR = 7.5), acute rejection (RR = 2.6), recipient male gender (RR = 3.6) and anti-HLA class II antibodies (RR = 2.9) and CAN-associated graft loss. In conclusion, the presence of anti-HLA class II antibodies conferred a risk for graft loss before a decline in renal function and increased the risk of graft failure in patients who already had a decline in graft function. Thus, anti-HLA class II antibody monitoring is a useful tool for the management of long-term kidney recipients.
authors.affiliation: Nephrology Division/Hospital do Rim e Hipertensão, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil.
authors.forename: E F
authors.initials: EF
authors.lastname: Campos
authors.forename: H
authors.initials: H
authors.lastname: Tedesco-Silva
authors.forename: P G
authors.initials: PG
authors.lastname: Machado
authors.forename: M
authors.initials: M
authors.lastname: Franco
authors.forename: J O
authors.initials: JO
authors.lastname: Medina-Pestana
authors.forename: M
authors.initials: M
authors.lastname: Gerbase-DeLima
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D003404:Creatinine / Q000097:blood; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000097:blood / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D014184:Transplantation, Homologous
chemical_list: D001323:Autoantibodies; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D003404:Creatinine